Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF

PIONEER-HF and the recently completed PARAGLIDE-HF both evaluated the efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF). This prespecified pooled analysis of PIONEER-HF (Ejection fraction [EF] ≤40%) and PARAGLIDE-HF (EF>40%) examines outcomes with sacubitril/valsartan in patients stabilized after a worsening HF event across the spectrum of EF.

Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: David A. Morrow, Eric Velazquez, Akshay Desai, Adam DeVore, Serge Lepage, Jeon-Gun Park, Kavita Sharma, Scott Solomon, Randall Starling, Jonathan Ward, Kristin Williamson, Shelley Zieroth, Adrian Hernandez, Robert Mentz, Eugene Braunwald Source Type: research